Artigos de revistas sobre o tema "Y220C"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Y220C".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Gener-Ricos, Georgina, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur et al. "TP53 Y220C Mutations in Patients with Myeloid Malignancies". Blood 142, Supplement 1 (28 de novembro de 2023): 1477. http://dx.doi.org/10.1182/blood-2023-189343.
Texto completo da fonteCarter, Bing Z., Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann et al. "Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2". Blood 142, Supplement 1 (28 de novembro de 2023): 2261. http://dx.doi.org/10.1182/blood-2023-181186.
Texto completo da fontePuzio-Kuter, Anna M., Chris Mulligan, Brandon Russo, Amy Wiebesiek, Lizhong Xu, Hong Yang, Binh Vu e Melissa Dumble. "Abstract 1295: Small molecule reactivators of Y220C mutant p53 modulate tumor infiltrating leukocytes and synergize with immune checkpoint inhibitors". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 1295. http://dx.doi.org/10.1158/1538-7445.am2022-1295.
Texto completo da fonteZheng, Qian, Peng Wang, Chen Liang, Yao Li, Xin Sun, Amin Li, Wei Zhang, Wei Long e Yanping Wang. "Abstract 5940: JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 5940. http://dx.doi.org/10.1158/1538-7445.am2024-5940.
Texto completo da fonteLiu, Meng, Kaijun Geng, Biao Lu, Yuanfeng Xia e Fanglong Yang. "Abstract 7275: GS-P-328, a brain-penetrant small molecule p53 Y220C reactivator for tumors harboring p53 Y220C mutation". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 7275. http://dx.doi.org/10.1158/1538-7445.am2024-7275.
Texto completo da fonteValenzuela-Chavira, Ignacio, Salvador Meneses-Sagrero, Aldo A. Arvizu-Flores, Javier Hernández-Paredes, Luisa Rascón-Valenzuela, Carlos A. Velázquez-Contreras e Ramón E. Robles-Zepeda. "Molecular Docking of the Cardenolides of Asclepias subulata in the Human p53 Protein Reveals an Interaction in the Cleft of the Y220C Mutant". Current Chemical Biology 15, n.º 3 (setembro de 2021): 222–33. http://dx.doi.org/10.2174/2212796815666211026112056.
Texto completo da fonteBauer, Matthias R., Rhiannon N. Jones, Raysa K. Tareque, Bradley Springett, Felix A. Dingler, Lorena Verduci, Ketan J. Patel, Alan R. Fersht, Andreas C. Joerger e John Spencer. "A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C". Future Medicinal Chemistry 11, n.º 19 (outubro de 2019): 2491–504. http://dx.doi.org/10.4155/fmc-2019-0181.
Texto completo da fonteBaud, Matthias G. J., Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger e Alan R. Fersht. "Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines". European Journal of Medicinal Chemistry 152 (maio de 2018): 101–14. http://dx.doi.org/10.1016/j.ejmech.2018.04.035.
Texto completo da fonteSchram, Alison M., Geoffrey I. Shapiro, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross et al. "Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation". Molecular Cancer Therapeutics 22, n.º 12_Supplement (1 de dezembro de 2023): LB_A25. http://dx.doi.org/10.1158/1535-7163.targ-23-lb_a25.
Texto completo da fonteLane, David P., e Chandra S. Verma. "Covalent Rescue of Mutant p53". Cancer Discovery 13, n.º 1 (9 de janeiro de 2023): 14–16. http://dx.doi.org/10.1158/2159-8290.cd-22-1212.
Texto completo da fonteRockwell, Nathan, Nicole Warrington e Joshua Rubin. "CBIO-22. p53 GAIN-OF-FUNCTION MUTATIONS DRIVE SEX SPECIFIC EFFECTS ON GLIOMA TUMORIGENESIS". Neuro-Oncology 22, Supplement_2 (novembro de 2020): ii20. http://dx.doi.org/10.1093/neuonc/noaa215.082.
Texto completo da fonteGomes, Sara, Bartolomeo Bosco, Joana B. Loureiro, Helena Ramos, Liliana Raimundo, Joana Soares, Nair Nazareth et al. "SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma". Cancers 11, n.º 8 (10 de agosto de 2019): 1151. http://dx.doi.org/10.3390/cancers11081151.
Texto completo da fonteGori, M., B. Barbaro, R. Maggio, M. Arciello, C. Viscomi e C. Balsano. "Protective effect of the Y220C mutant p53 during steatosis: Good news?" Digestive and Liver Disease 45 (outubro de 2013): e368-e369. http://dx.doi.org/10.1016/j.dld.2013.09.010.
Texto completo da fonteMiller, Jessica J., Christophe Orvain, Shireen Jozi, Ryan M. Clarke, Jason R. Smith, Anaïs Blanchet, Christian Gaiddon, Jeffrey J. Warren e Tim Storr. "Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer". Chemistry - A European Journal 24, n.º 67 (9 de novembro de 2018): 17734–42. http://dx.doi.org/10.1002/chem.201802677.
Texto completo da fonteGori, Manuele, Barbara Barbaro, Mario Arciello, Roberta Maggio, Carmela Viscomi, Alessia Longo e Clara Balsano. "Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?" Journal of Cellular Physiology 229, n.º 9 (23 de maio de 2014): 1182–92. http://dx.doi.org/10.1002/jcp.24550.
Texto completo da fonteGori, M., B. Barbaro, M. Arciello, R. Maggio, C. Viscomi, A. Longo e C. Balsano. "Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?" Journal of Cellular Physiology 230, n.º 6 (25 de fevereiro de 2015): 1400. http://dx.doi.org/10.1002/jcp.24874.
Texto completo da fonteDixit, Updesh, Ashutosh K. Pandey, Zhihe Liu, Sushil Kumar, Matthew B. Neiditch, Kenneth M. Klein e Virendra N. Pandey. "FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53". Journal of Virology 89, n.º 15 (20 de maio de 2015): 7905–21. http://dx.doi.org/10.1128/jvi.00729-15.
Texto completo da fonteGener-Ricos, Georgina, Koji Sasaki, Sanam Loghavi, Abhishek Maiti, Nicholas Short, Fadi Haddad, Naval Daver et al. "A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies". Blood 140, Supplement 1 (15 de novembro de 2022): 11830–32. http://dx.doi.org/10.1182/blood-2022-167923.
Texto completo da fonteRauf, Shah Md Abdur, Akira Endou, Hiromitsu Takaba e Akira Miyamoto. "Effect of Y220C Mutation on p53 and Its Rescue Mechanism: A Computer Chemistry Approach". Protein Journal 32, n.º 1 (janeiro de 2013): 68–74. http://dx.doi.org/10.1007/s10930-012-9458-x.
Texto completo da fonteSHEN, Hong-Chen, Ji-Yong DING, Li LI e Fu-Feng LIU. "Effect of Y220C Mutant on the Conformational Transition of p53C Probed by Molecular Dynamics Simulation". Acta Physico-Chimica Sinica 32, n.º 10 (2016): 2620–27. http://dx.doi.org/10.3866/pku.whxb201606224.
Texto completo da fontevan Kempen, Pauline M. W., Froukje J. Verdam, Eyleen de Poel, Weibel W. Braunius, Roel A. de Weger, Robert J. J. van Es, Wilko Grolman e Stefan M. Willems. "TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma". Pathobiology 82, n.º 1 (2015): 21–27. http://dx.doi.org/10.1159/000369102.
Texto completo da fonteKhadiullina, Raniya, Regina Mirgayazova, Damir Davletshin, Elvina Khusainova, Vitaly Chasov e Emil Bulatov. "Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry". Life 13, n.º 1 (22 de dezembro de 2022): 31. http://dx.doi.org/10.3390/life13010031.
Texto completo da fonteBauer, Matthias R., Rhiannon N. Jones, Matthias G. J. Baud, Rainer Wilcken, Frank M. Boeckler, Alan R. Fersht, Andreas C. Joerger e John Spencer. "Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs". ACS Chemical Biology 11, n.º 8 (21 de junho de 2016): 2265–74. http://dx.doi.org/10.1021/acschembio.6b00315.
Texto completo da fonteAccordino, Sebastián R., J. Ariel Rodríguez Fris e Gustavo A. Appignanesi. "Wrapping Effects within a Proposed Function-Rescue Strategy for the Y220C Oncogenic Mutation of Protein p53". PLoS ONE 8, n.º 1 (24 de janeiro de 2013): e55123. http://dx.doi.org/10.1371/journal.pone.0055123.
Texto completo da fonteBasse, Nicolas, Joel L. Kaar, Giovanni Settanni, Andreas C. Joerger, Trevor J. Rutherford e Alan R. Fersht. "Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant". Chemistry & Biology 17, n.º 1 (janeiro de 2010): 46–56. http://dx.doi.org/10.1016/j.chembiol.2009.12.011.
Texto completo da fonteShokat, Kevan M. "Abstract IA08: Direct covalent inhibitors of mutant K-Ras". Molecular Cancer Research 21, n.º 5_Supplement (1 de maio de 2023): IA08. http://dx.doi.org/10.1158/1557-3125.ras23-ia08.
Texto completo da fonteYu, Camilla, Aaron Petty e Roberto Vargas. "Abstract 4885: APR-246 cytotoxic effects are TP53 independent in endometrial cancer cell lines". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 4885. http://dx.doi.org/10.1158/1538-7445.am2023-4885.
Texto completo da fonteAhire, Vidhula, D. Das, Kaushala Prasad Mishra, G. R. Kulkarni e L. Ackland. "Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy". Journal of Environmental Pathology, Toxicology and Oncology 35, n.º 4 (2016): 355–64. http://dx.doi.org/10.1615/jenvironpatholtoxicoloncol.2016012256.
Texto completo da fonteBromley, Dennis, Matthias R. Bauer, Alan R. Fersht e Valerie Daggett. "Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein". Protein Engineering Design and Selection 29, n.º 9 (8 de agosto de 2016): 377–90. http://dx.doi.org/10.1093/protein/gzw035.
Texto completo da fonteLuparello, Claudio, Ilenia Cruciata, Andreas C. Joerger, Cory A. Ocasio, Rhiannon Jones, Raysa Khan Tareque, Mark C. Bagley et al. "Genotoxicity and Epigenotoxicity of Carbazole-Derived Molecules on MCF-7 Breast Cancer Cells". International Journal of Molecular Sciences 22, n.º 7 (26 de março de 2021): 3410. http://dx.doi.org/10.3390/ijms22073410.
Texto completo da fonteBhuvaneshwari, C., e S. Ambiga. "Antioxidant and anticancer activities of Solanum nigrum Linn leaves". Journal of Current Opinion in Crop Science 3, n.º 2 (28 de junho de 2022): 79–89. http://dx.doi.org/10.62773/jcocs.v3i2.171.
Texto completo da fonteArciello, Mario, Alessia Longo, Carmela Viscomi, Concetta Capo, Antonio Angeloni, Luisa Rossi e Clara Balsano. "Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload". BioMetals 28, n.º 6 (5 de outubro de 2015): 1017–29. http://dx.doi.org/10.1007/s10534-015-9886-0.
Texto completo da fonteTseng, Tsui-Hwa, Chau-Jong Wang, Yean-Jang Lee, Yi-Chia Shao, Chien-Heng Shen, Ko-Chao Lee, Shui-Yi Tung e Hsing-Chun Kuo. "Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol". International Journal of Molecular Sciences 23, n.º 9 (4 de maio de 2022): 5102. http://dx.doi.org/10.3390/ijms23095102.
Texto completo da fonteTseng, Tsui-Hwa, Yi-Chia Shao, Yean-Jang Lee e Huei-Jane Lee. "2-(4-Benzyloxy-3-methoxyphenyl)-5-(carbethoxyethylene)-7-methoxy-benzofuran, a Benzofuran Derivative, Suppresses Metastasis Effects in P53-Mutant Hepatocellular Carcinoma Cells". Biomedicines 11, n.º 7 (19 de julho de 2023): 2027. http://dx.doi.org/10.3390/biomedicines11072027.
Texto completo da fonteLv, Cuiting, Aihua Lan, Xiao Fan, Caiguo Huang e Gong Yang. "Asperolide A induces apoptosis and cell cycle arrest of human hepatoma cells with p53-Y220C mutant through p38 mediating phosphorylation of p53 (S33)". Heliyon 9, n.º 3 (março de 2023): e13843. http://dx.doi.org/10.1016/j.heliyon.2023.e13843.
Texto completo da fonteCheng, Ya-Yun, Denise Prosser, Liudmila Velikokhatnaya e Anna Lokshin. "Abstract 5833: Functional characterization of TP53 mutations in human fallopian tube secretory epithelial cells". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 5833. http://dx.doi.org/10.1158/1538-7445.am2022-5833.
Texto completo da fontePetty, Aaron, Arda Durmaz, Brian Yard, Jacob Scott e Roberto Vargas. "Abstract 1090: Dominant-negative TP53 variants confer radiation resistance in endometrial cancer". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1090. http://dx.doi.org/10.1158/1538-7445.am2023-1090.
Texto completo da fonteYang, Yaxian, Heran Wang, Lucas Wang, WenTao Fan, Bin Lian, Ying Jin, Weiquan Luo et al. "Frequency and patterns of TP53 mutations in lung cancer." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junho de 2023): e21013-e21013. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21013.
Texto completo da fonteBabatunde, Olayode, Ryan Quin Notti e William D. Tap. "Characterizing TP53 mutations in bone and soft tissue sarcoma." Journal of Clinical Oncology 42, n.º 16_suppl (1 de junho de 2024): e23521-e23521. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23521.
Texto completo da fonteMoses, Renyta, Ryan Hausler, Gregory Kelly, Alexandra Indeglia, Sven Miller, John Karanicolas, Maureen Murphy e Kara Maxwell. "Abstract 3025: Germline p53 R181 variants and DNA binding cooperativity in tumorigenesis". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 3025. http://dx.doi.org/10.1158/1538-7445.am2024-3025.
Texto completo da fonteNesline, Mary K., Paul DePietro, Maureen Cooper, Shengle Zhang, Sarah Howarth, Zachary D. Wallen, Michael D. Biorn et al. "The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junho de 2023): 6506. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6506.
Texto completo da fonteBattaglin, Francesca, Andrew Elliott, Joanne Xiu, Sandra Algaze, Jingyuan Wang, Priya Jayachandran, Shivani Soni et al. "Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC)." Journal of Clinical Oncology 42, n.º 3_suppl (20 de janeiro de 2024): 552. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.552.
Texto completo da fonteSteinbuck, Martin P., Xavier Cabana-Puig, Erica Palmer, Mimi M. Jung, Thomas Williams, Kristen Osaer, Jeff Zhang, Christopher M. Haqq e Peter C. DeMuth. "Abstract 4099: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 4099. http://dx.doi.org/10.1158/1538-7445.am2024-4099.
Texto completo da fonteSuehnholz, Sarah P., Moriah Nissan, Hongxin Zhang, Ritika Kundra, Calvin Lu, Amanda Dhaneshwar, Nicole Fernandez et al. "Abstract 6585: OncoKB, MSK’s precision oncology knowledge base". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6585. http://dx.doi.org/10.1158/1538-7445.am2023-6585.
Texto completo da fonteKim, Peter, Parisa Malekzadeh, Nolan Vale, Elizabeth Hedges, Nikolaos Zacharakis e Steven Rosenberg. "152 Adoptive T cell therapy targeting somatic p53 mutations". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (novembro de 2020): A165—A166. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0152.
Texto completo da fonteVan Alsten, Sarah, Ebonee Butler, Benjamin Calhoun, Michael Love, Charles Perou, Katherine A. Hoadley e Melissa Troester. "Abstract PO1-08-12: Genomic Characterization of the Carolina Breast Cancer Study". Cancer Research 84, n.º 9_Supplement (2 de maio de 2024): PO1–08–12—PO1–08–12. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-08-12.
Texto completo da fonteDeb, S., S. Bandyopadhyay e S. Roy. "Spectroscopic study of Y210C lambda-repressor: implications for cooperative interaction". Protein Engineering Design and Selection 11, n.º 6 (1 de junho de 1998): 481–87. http://dx.doi.org/10.1093/protein/11.6.481.
Texto completo da fonteДемидова, Т. Е., И. Н. Чижевская e А. Е. Чижевский. "Formation of historical memory of students by means of network project activities". Management of Education 14, n.º 1-1(74) (15 de janeiro de 2024): 165–74. http://dx.doi.org/10.25726/y2202-2949-1521-f.
Texto completo da fonteBauer, Matthias R., Andreas Krämer, Giovanni Settanni, Rhiannon N. Jones, Xiaomin Ni, Raysa Khan Tareque, Alan R. Fersht, John Spencer e Andreas C. Joerger. "Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm". ACS Chemical Biology 15, n.º 3 (28 de janeiro de 2020): 657–68. http://dx.doi.org/10.1021/acschembio.9b00748.
Texto completo da fonteCarter, Bing Z., Po Yee Mak, Wenjing Tao, Lauren B. Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub et al. "Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics". Blood 138, Supplement 1 (5 de novembro de 2021): 2239. http://dx.doi.org/10.1182/blood-2021-148014.
Texto completo da fonte